Cas No. 1491150-22-1, 5-Bromo-6-chloro-N-(4-(chlorodifluoromethoxy)phenyl)nicotinamide

As a novel BCR-ABL inhibitor, Asciminib offers a highly targeted therapy that tackles CML with remarkable efficacy and improved safety profile. With its innovative mechanism of action and potential to overcome resistance mutations, Asciminib represents a significant advancement in the management of CML. By incorporating Asciminib into your pharmaceutical portfolio, you can empower patients with this innovative and life-changing treatment option. Join the fight against CML with Asciminib and make a lasting impact on patient care.